Royalty Pharma /
Denali
Royalty Pharma to fund Denali in exchange for a royalty
Source for the buyer and target: Denali Therapeutics Inc.
For the buyer and target.
““We are delighted to partner with Denali and acquire a royalty on tividenofusp alfa, an innovative therapy that addresses a significant unmet need in the cognitive and physical manifestations of Hunter syndrome,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma.”
Published 4 Dec 2025
Open the sourceWhat happened
Royalty Pharma plc agreed to provide Denali Therapeutics Inc. with up to $275 million in funding in exchange for a royalty on future net sales of tividenofusp alfa. [01]
The transaction is subject to closing conditions, including FDA accelerated approval of tividenofusp alfa on or before June 30, 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Royalty Pharma to fund Denali in exchange for a royalty
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“The transaction is subject to closing conditions, including FDA accelerated approval of tividenofusp alfa on or before June 30, 2026”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly